1 option
Development of PRO-140 (Leronlimab) as a treatment for COVID-19 / Jacob Lalezari.
- Format:
- Sound recording
- Author/Creator:
- Lalezari, Jacob (Quest Clinical Research, USA), Speaker.
- Series:
- Henry Stewart talks. Biomedical & life sciences collection. Interviews on Covid-19.
- Interviews on Covid-19, 2056-452X
- Language:
- English
- Subjects (All):
- Coronavirus infections--Treatment.
- Coronavirus infections.
- COVID-19 (Disease).
- Drug development.
- CCR5 Receptor Antagonists--therapeutic use.
- Coronavirus Infections--drug therapy.
- COVID-19 Drug Treatment.
- Drug Development.
- Inflammation.
- Antibodies, Monoclonal, Humanized.
- Pharmaceutical Preparations.
- Receptors, CCR5.
- SARS-CoV-2.
- HIV Antibodies.
- Medical Subjects:
- CCR5 Receptor Antagonists--therapeutic use.
- Coronavirus Infections--drug therapy.
- COVID-19 Drug Treatment.
- Drug Development.
- Inflammation.
- Antibodies, Monoclonal, Humanized.
- Pharmaceutical Preparations.
- Receptors, CCR5.
- SARS-CoV-2.
- HIV Antibodies.
- Physical Description:
- 1 online resource (1 streaming audio file (19 min., 48 sec.))
- Place of Publication:
- London : Henry Stewart Talks, 2020.
- Contents:
- Contents: Previous indications for Leronlimab
- Leronlimab is a CCR5 receptor antagonist
- CCR5 receptor function in inflammation and disease
- Clinical limitations of blocking CCR5 receptors
- How will Leronlimab be used in the clinic?
- When can we expect a preliminary approval?
- Notes:
- Description based on publisher supplied metadata and other sources.
- Audio interview.
- Title from title frames.
- Publisher Number:
- 8159 Henry Stewart Talks
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.